Zoonotic diseases pose a significant global health threat, driven by factors such as globalization, climate change, urbanization, antimicrobial resistance (AMR), and intensified human–animal interactions. The increasing interconnectedness of human, animal, and environmental health underscores the importance of the OH paradigm in addressing zoonotic threats in a globalized world. This review explores the complex epidemiology of zoonotic diseases, the challenges associated with their management, and the necessity for cross-sector collaboration to enhance prevention and control efforts. Key public health strategies, including surveillance systems, infection control measures, and community education programs, play crucial roles in mitigating outbreaks. However, gaps in governance, resource allocation, and interdisciplinary cooperation hinder effective disease management, particularly in low- and middle-income countries (LMICs). To illustrate the effectiveness of the OH approach, this review highlights successful programs, such as the PREDICT project, Rwanda’s National One Health Program, the EcoHealth Alliance, and the Rabies Elimination Program in the Philippines. These initiatives demonstrate how integrating human, animal, and environmental health efforts can enhance early detection, improve outbreak responses, and reduce public health burdens. Strengthening global health governance, enhancing surveillance infrastructure, regulating antimicrobial use, and investing in research and technological innovations are essential steps toward mitigating zoonotic risks. Ultimately, a coordinated, multidisciplinary approach is vital for addressing the dynamic challenges posed by zoonotic diseases and ensuring global health security in an increasingly interconnected world.

Background: Antimicrobial resistance (AMR) poses a global health threat, particularly in low- and middle-income countries (LMICs). Clustered regularly interspaced short palindromic repeats (CRISPR)–Cas system technology offers a promising tool to combat AMR by targeting and disabling resistance genes in WHO bacterial priority pathogens. Thus, we systematically reviewed the potential of CRISPR–Cas technology to address AMR. Methods: This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted using the Scopus and PubMed databases, focusing on publications from 2014 to June 2024. Keywords included “CRISPR/Cas,” “antimicrobial resistance,” and “pathogen.” The eligibility criteria required original studies involving CRISPR/Cas systems that targeted AMR. Data were extracted from eligible studies, qualitatively synthesized, and assessed for bias using the Joanna Briggs Institute (JBI)-standardized tool. Results: Data from 48 eligible studies revealed diverse CRISPR–Cas systems, including CRISPR–Cas9, CRISPR–Cas12a, and CRISPR–Cas3, targeting various AMR genes, such as blaOXA-232, blaNDM, blaCTX-M, ermB, vanA, mecA, fosA3, blaKPC, and mcr-1, which are responsible for carbapenem, cephalosporin, methicillin, macrolide, vancomycin, colistin, and fosfomycin resistance. Some studies have explored the role of CRISPR in virulence gene suppression, including enterotoxin genes, tsst1, and iutA in Staphylococcus aureus and Klebsiella pneumoniae. Delivery mechanisms include bacteriophages, nanoparticles, electro-transformation, and conjugative plasmids, which demonstrate high efficiency in vitro and in vivo. CRISPR-based diagnostic applications have demonstrated high sensitivity and specificity, with detection limits as low as 2.7 × 10² CFU/mL, significantly outperforming conventional methods. Experimental studies have reported significant reductions in resistant bacterial populations and complete suppression of the targeted strains. Engineered phagemid particles and plasmid-curing systems have been shown to eliminate IncF plasmids, cured plasmids carrying vanA, mcr-1, and blaNDM with 94% efficiency, and restore antibiotic susceptibility. Gene re-sensitization strategies have been used to restore fosfomycin susceptibility in E. coli and eliminate blaKPC-2-mediated carbapenem resistance in MDR bacteria. Whole-genome sequencing and bioinformatics tools have provided deeper insights into CRISPR-mediated defense mechanisms. Optimization strategies have significantly enhanced gene-editing efficiencies, offering a promising approach for tackling AMR in high-priority WHO pathogens. Conclusions: CRISPR–Cas technology has the potential to address AMR across priority WHO pathogens. While promising, challenges in optimizing in vivo delivery, mitigating potential resistance, and navigating ethical-regulatory barriers must be addressed to facilitate clinical translation.

Vesicular stomatitis virus (VSV) represents a significant advancement in therapeutic medicine, offering unique molecular and cellular characteristics that make it exceptionally suitable for medical applications. The bullet-shaped morphology, RNA genome organization, and cytoplasmic replication strategy provide fundamental advantages for both vaccine development and oncolytic applications. VSV’s interaction with host cells through the low-density lipoprotein receptor (LDL-R) and its sophisticated transcriptional regulation mechanisms enables precise control over therapeutic applications. The virus demonstrates remarkable versatility through its rapid replication cycle, robust immune response induction, and natural neurotropism. Recent technological innovations in VSV engineering have led to enhanced safety protocols and improved therapeutic modifications, particularly in cancer treatment. Attenuation strategies have successfully addressed safety concerns while maintaining the therapeutic efficacy of the virus. The molecular and cellular interactions of VSV, particularly its immune modulation capabilities and tumor-selective properties, have proven valuable in the development of targeted therapeutic strategies. This review explores these aspects, while highlighting the continuing evolution of VSV-based therapeutic approaches in precision medicine.

Cholera is an enteric disease caused by the ingestion of food or water contaminated by the toxins of the bacteria - Vibrio Cholerae. Its transmission is exacerbated by poor sanitary conditions and poor hygiene practices. Affected individuals may present with severe symptoms such as watery diarrhoea and vomiting that can lead to death within few hours. Cameroon is experiencing its worst cholera outbreak in decades. The outbreak is severest in the South-West and the Littoral regions. As of the time of writing, in six regions of the country, 6652 suspected cases of cholera including 134 deaths (CFR 2%) have been reported and the number is rising. Shortage of safe drinking water and contamination of rivers has exacerbated the outbreak, especially in the rural and hard to reach communities. The trans-border movement at the South-West region, defecation in the open and on rivers, and overcrowding at the Littoral region have been particularly challenging towards curbing the outbreak. Despite the challenges, Cameroon's health authorities have been working to bring the situation under control by engaging in community sensitization on good hygiene habits, disinfection of houses and vaccination campaigns. In the light of these, it is recommended that Cameroon should improve and strengthen its vaccination campaign across the country. Adequate health systems should be established at the point of entry to prevent cross-border cholera transmission and retransmission. Access to hard to reach communities should be improved so that vaccines and basic health care and sanitation services such as provision of safe drinking water can be provided.

Immunization remains a vital pillar of Nigeria’s public health agenda, significantly reducing the burden of vaccine-preventable diseases. However, the success of immunization programs hinges not only on vaccine access and delivery but also on robust post-vaccination surveillance systems that ensure vaccine safety and foster public confidence. In Nigeria, post-vaccination pharmacovigilance, led by the National Agency for Food and Drug Administration and Control (NAFDAC), faces critical challenges, including underreporting of adverse events following immunization (AEFIs), inadequate healthcare worker training, infrastructural limitations, and the widespread influence of misinformation. These systemic weaknesses threaten to undermine vaccine confidence, particularly in underserved and rural areas. The aim of this study was to examine the current state of Nigeria’s post-vaccination surveillance infrastructure, highlighting gaps in AEFI reporting and data management. Drawing on global best practices and successful models from other low- and middle-income countries (LMICs), this study proposes a set of strategic interventions to strengthen pharmacovigilance. These include the adoption of digital and mobile health technologies, capacity building for healthcare providers, community engagement, and integration of artificial intelligence in safety signal detection. This study underscores the urgency of regulatory reform and private sector inclusion, advocating a holistic and sustainable approach to vaccine safety monitoring. By reinforcing pharmacovigilance systems, Nigeria can build public confidence, improve vaccine uptake, and enhance the overall effectiveness of its national immunization program.